Literature DB >> 11086036

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.

A L Marzo1, B F Kinnear, R A Lake, J J Frelinger, E J Collins, B W Robinson, B Scott.   

Abstract

A number of tumor studies have indicated a link between CD4 help and the magnitude and persistence of CTL activity; however, the mechanisms underlying this have been largely unclear. To evaluate and determine the mechanisms by which CD4(+) T cells synergize with CD8(+) T cells to prevent tumor growth, we used the novel technique of monitoring in vivo CTL by labeling target cells with CFSE. This approach was supported by the direct visualization of CTL using peptide-MHC tetramers to follow tumor-specific T cells. The data presented demonstrate that while cotransfer of Ag-specific CD4(+) T cells was not required for the generation of CTLs, because adoptive transfer of CD8(+) T cells alone was sufficient, CD4(+) T cells were required for the maintenance of CD8(+) T cell numbers. Our data suggest that there is a correlation among the number of CD8(+) T cells, in vivo CTL function, and IFN-gamma production, with no evidence of a partial or nonresponsive phenotype among tetramer-positive cells. We also show that CD4(+) T cells are required for CD8(+) T cell infiltration of the tumor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086036     DOI: 10.4049/jimmunol.165.11.6047

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  107 in total

Review 1.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

2.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

3.  DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency.

Authors:  Chien-Fu Hung; Ya-Chea Tsai; Liangmei He; T-C Wu
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

4.  Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Authors:  Gerrit Weber; Ignazio Caruana; Rayne H Rouce; A John Barrett; Ulrike Gerdemann; Ann M Leen; Karen R Rabin; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

5.  CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.

Authors:  Hui Huang; Siguo Hao; Fang Li; Zhenmin Ye; Junbao Yang; Jim Xiang
Journal:  Immunology       Date:  2007-02       Impact factor: 7.397

Review 6.  Langerhans cells as targets for immunotherapy against skin cancer.

Authors:  Patrizia Stoitzner; Florian Sparber; Christoph H Tripp
Journal:  Immunol Cell Biol       Date:  2010-03-30       Impact factor: 5.126

7.  Immunology: A helpers' guide to infection.

Authors:  Thomas Gebhardt; Francis R Carbone
Journal:  Nature       Date:  2009-11-26       Impact factor: 49.962

8.  Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Authors:  Aikaterini Hatzioannou; Saba Nayar; Anastasios Gaitanis; Francesca Barone; Constantinos Anagnostopoulos; Panayotis Verginis
Journal:  Oncoimmunology       Date:  2016-07-29       Impact factor: 8.110

9.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

10.  Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

Authors:  Michael Y Gerner; Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.